@AACR

Bhaarath PG· @BhaarathP10039 · X·2026-04-20 02:46· 2026-04-20评分60

正文 · 机器翻译

热度 1 · 1 赞 · 0 回复 · 0 转发

会议摘要

CT002NCT06270706按代号 PLN-101095 对上

First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Timothy A. Yap, Andrae Vandross, Jenny Amaya-Amaya, Chris N. Barnes, Shuguang Ma, Martin Decaris, Keithryn Nicolas, Alexander Spira, Jacqueline Brown, Patricia LoRusso, Manish R. Sharma

读摘要原文 →

CT215NCT05379985 NCT06881784按代号 RMC-6236 对上

RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson

读摘要原文 →

1884按代号 RMC-6236 对上

Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models.

Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz

读摘要原文 →

4478按代号 RMC-6236 对上

Synergistic antitumor activity of tumor-treating fields and multiselect-RAS (ON) inhibitor RMC-6236 in pancreatic ductal adenocarcinoma.

Ishita Saha, Santanu Bhattacharya, Debabrata Mukhopadhyay, Hani M. Babiker

读摘要原文 →

5996按代号 RMC-6236 对上

Evaluating the effects of the Pan-KRas inhibitor RMC-6236 in KRas-mutant colorectal cancer cells

Seema nadir, Sumaiya Binte Hamid, Mati Ur Rehman, Azhar Hussain Rajabali, Kulsoom K. Ghias, Arooj Shafiq

读摘要原文 →

来源：Bhaarath PG · x.com